Edgar Filing: Berelowitz Michael - Form 4/A

Berelowitz	Michael									
Form 4/A May 10, 20	18									
FORM	ЛЛ								PPROVAL	
	UNITED		CURITIES A Washington			NGE	COMMISSIO	N OMB Number:	3235-0287	7
Check t if no los subject Section	ANGES IN SECUE		ICIA	Estimated	Expires: January 31, 2005 Estimated average burden hours per					
Form 4								response	•	5
Form 5 obligati may co <i>See</i> Inst 1(b).	ons ntinue. Section 17	(a) of the Publi		ding Cor	npan	y Act	nge Act of 1934, of 1935 or Secti 940			
(Print or Type	Responses)									
1. Name and Berelowitz	Address of Reporting Michael	Sym	ssuer Name and ool ro Pharma, Ii			ing	5. Relationship Issuer	of Reporting Per	rson(s) to	
(Lest)	(Einst)			-	пј		(Ch	eck all applicabl	e)	
(Last) C/O RECE LAPP ROA	RO PHARMA, IN	(Mor	nte of Earliest T hth/Day/Year) 04/2018	ransaction			X_ Director Officer (gi below)		% Owner her (specify	
	(Street)	4. If	Amendment, D	ate Origina	ıl		6. Individual or	Joint/Group Fili	ng(Check	
MALVER	N, PA 19355		Filed(Month/Day/Year) 05/08/2018				Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
(City)	(State)	(Zip)		~ • •	~		Person			
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		3. if Transactio Code	4. Securit nAcquired Disposed (Instr. 3, 4	ies (A) or of (D)	r)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect	
Reminder: Re	eport on a separate lin	e for each class of	securities benef	-		-	or indirectly.	ection of	SEC 1474	

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02) required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number	6. Date Exercisable and	7. Title and Amount of	8. I
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	onof Derivative	Expiration Date	Underlying Securities	Der
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	Sec

Edgar Filing: Berelowitz Michael - Form 4/A

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr.	8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)					
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 11.32	05/04/2018		A		8,965 (1)		<u>(2)</u>	05/04/2028	Common Stock	8,965

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
Berelowitz Michael C/O RECRO PHARMA, INC. 490 LAPP ROAD MALVERN, PA 19355	Х							
Signatures								
/s/ Ryan Lake,	05/1	0/2010						

 Attorney-in-fact
 05/10/2018

 **Signature of Reporting Person
 Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This amended Form 4 is being filed to correct a typographical error in the number of stock options acquired on May 4, 2018 as reported on the Form 4 filed on May 8, 2018.
- (2) The stock option will vest on May 4, 2019.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

(In